Table 2.
Baseline demographic data
| Demographics | Ghofrani et al30
|
Ghofrani et al11
|
Simonneau et al31
|
|
|---|---|---|---|---|
| Riociguat (n=41) | Placebo (n=88) | Riociguat (n=173) | Riociguat (n=237) | |
| Age, mean ± SD, years | 63 (56–70)a | 59±13 | 59±14 | 59±13 |
| Female, n (%) | 18 (44) | 54 (61) | 118 (68) | 153 (65) |
| Operable status, n (%) | ||||
| Inoperable | 41 (100) | 68 (77) | 121 (70) | 172 (73) |
| Postoperative | 0 (0) | 20 (23) | 52 (30) | 65 (27) |
| WHO functional class, n (%) | ||||
| I | 0 (0) | 0 | 3 (2) | 1 |
| II | 10 (24) | 25 (28) | 55 (32) | 31 |
| III | 31 (76) | 60 (68) | 107 (62) | 65 |
| IV | 0 (0) | 2 (2) | 8 (5) | 3 |
| 6-minute walk distance, mean ± SD, m | 390 (330–441)a | 356±75 | 342±82 | 351±78 |
| Right heart catheterization, mean ± SD | ||||
| mPAP, mmHg | 44 (38–51)a | 44±10 | 45±13 | – |
| PVR, dyn⋅s/cm5 | 686 (516–859)a | 779±401 | 791±432 | – |
| Cardiac index, L/min/m2 | 2.31 (1.94–2.68)a | – | – | – |
| Cardiac output, L/min | – | 4±1 | 4±1 | – |
Notes:
Median (interquartile range). – Not reported. From N Engl J Med, Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension, 369(4):319–329, Copyright © 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.11 Reproduced with permission of the European Respiratory Society ©: European Respiratory Journal Oct 2010, 36(4):792–799. DOI: 10.1183/09031936.30 Reproduced with permission of the European Respiratory Society ©: European Respiratory Journal May 2015, 45(5):1293–1302. DOI: 10.1183/09031936.00087114.31
Abbreviations: SD, standard deviation; WHO, World Health Organization; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance.